Biotech | February 18, 2022
USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
The entire integration and transition of the brands is expected to be completed by March 2022
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Subscribe To Our Newsletter & Stay Updated
